Novartis buys Arvinas’ prostate cancer protein degrader for $150m
Drug Discovery World
APRIL 17, 2024
Biotechnology company Arvinas has entered into an exclusive strategic license agreement with Novartis for ARV-766, Arvinas’ second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer. Arvinas will receive an upfront payment in the aggregate amount of $150 million.
Let's personalize your content